Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: A dual-center, propensity score matched analysis

Ruxolitinib is a JAK1/2 inhibitor approved for the treatment of myelofibrosis (MF) and polycythemia vera (PV). Recent data has suggested the possibility of increased infectious and secondary malignancy rates in patients treated with ruxolitinib. We conducted a dual-center, retrospective study of 202...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Leuk Lymphoma
Huvudupphovsmän: Tremblay, Douglas, King, Amber, Li, Lihua, Moshier, Erin, Coltoff, Alexander, Koshy, Anita, Kremyanskaya, Marina, Hoffman, Ronald, Mauro, Michael J., Rampal, Raajit K., Mascarenhas, John
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2019
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7771191/
https://ncbi.nlm.nih.gov/pubmed/31711337
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2019.1688323
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk